Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the 11 Dirt Cheap Stocks to Buy According to Analysts. On October 3 ...

Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US.

CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...

The pharmaceutical company has also earned approval for Wegovy in treating metabolic dysfunction-associated steatohepatitis ...

Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...

Fintel reports that on October 20, 2025, D. Boral Capital maintained coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. Analyst Price Forecast Suggests 632.76% Upside As of September ...

Rani Therapeutics stock surged 200% after securing a $1 billion partnership with Chugai and raising $60 million in funding.

Market experts believe that Samvat 2082 could usher in an earnings-led recovery, supported by structural reforms, GST 2.0, ...

An investigational treatment, used in combination with another cancer medication, took an important step forward after ...

Disc Medicine earns a Strong Buy rating as bitopertin advances for EPP/XLP, with FDA review fast-tracked and strong funding.

These Goldman Sachs stock picks are poised for growth in 2026 and will continue to pay and raise their significant and ...